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According to clinical and pre-clinical studies, oxidative stress and its consequences may be the cause or, 
at least, a contributing factor, to a large number of neurodegenerative diseases. These diseases include 
common and debilitating disorders, characterized by progressive and irreversible loss of neurons in 
specific regions of the brain. The most common neurodegenerative diseases are Parkinson’s disease, 
Huntington’s disease, Alzheimer’s disease and amyotrophic lateral sclerosis. Coenzyme Q
10
 (CoQ
10
) has 
been extensively studied since its discovery in 1957. It is a component of the electron transportation chain 
and participates in aerobic cellular respiration, generating energy in the form of adenosine triphosphate 
(ATP). The property of CoQ
10
 to act as an antioxidant or a pro-oxidant, suggests that it also plays an 
important role in the modulation of redox cellular status under physiological and pathological conditions, 
also performing a role in the ageing process. In several animal models of neurodegenerative diseases, 
CoQ
10
 has shown beneficial effects in reducing disease progression. However, further studies are needed 
to assess the outcome and effectiveness of CoQ
10
 before exposing patients to unnecessary health risks 
at significant costs.
Uniterms: Coenzyme Q
10
. Antioxidant. Oxidative stress. Neurodegenerative diseases.
De acordo com estudos clínicos e pré-clínicos, o estresse oxidativo e suas conseqüências podem ser a 
causa, ou, no mínimo, o fator que contribui para grande número de doenças degenerativas. Estas doenças 
incluem problemas comuns e debilitantes, caracterizados por perda progressiva e irreversível de neurônios 
em regiões específicas do cérebro. As doenças degenerativas mais comuns são doença de Parkinson, de 
Hutington, de Alzheimer e esclerose amiotrófica lateral. A Coenzima Q
10
 (CoQ
10
) tem sido intensamente 
estudada desde sua descoberta, em 1957. É um componente da cadeia de transporte eletrônico e participa 
da respiração aeróbica celular, gerando energia na forma de trifosfato de adenosina (ATP). A propriedade 
da CoQ
10 
de atuar
 
como antioxidante ou pró-oxidante sugere papel importante na modulação do estado 
redox celular sob condições fisiológicas e patológicas, desempenhando, também, papel no processo de 
envelhecimento. Em vários modelos animais de doenças neurodegenerativas, a CoQ
10 
mostrou efeitos 
benéficos na redução do curso da doença. Entretanto, há necessidade de estudos adicionais para avaliar o 
efeito e a eficácia da CoQ
10 
 antes de expor os pacientes a riscos de saúde desnecessários e de alto custo.
Unitermos: Coenzima Q
10
. Antioxidante. Estresse oxidativo. Doenças neurodegenerativas.
INTRODUCTION
The Coenzyme Q
10
 (2,3-dimethoxy-5-methyl-6-
decaprenil-1,4-benzoquinone) is a liposoluble substance 
also known as CoQ
10
, vitamin Q
10
, ubidecarenone or ubi-
quinone (Figure 1) (Bonakdar, Guarneri, 2005 ; Schoepp, 
1999; Pepping, 1999). It can be obtained from the diet 
or supplements, but is also produced endogenously. It is 
found mainly in the mitochondria, the cellular organelles 
for energy production.
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Meat, poultry and fish are the richest sources of 
CoQ
10
, and the daily intake of these foods provides between 
2 to 20 mg, which does not significantly increase the levels 
of CoQ
10
 in blood and tissues. Small amounts are found in 
cereals, soybeans, nuts and vegetables, particularly spinach 
and broccoli (Kitano et al., 2006, Mason, 2005). The ab-
sorption of CoQ
10
 from the diet (or supplements) occurs in 
the small intestine and is influenced by the presence of food 
and beverages. It is better absorbed in the presence of foods 
rich in lipids. After being absorbed, the CoQ
10
 is transported 
to the liver where it is incorporated into lipoproteins and 
concentrated in tissues (Mason, 2005).
CoQ
10
 is produced from tyrosine in all cells of the 
body, but especially in the heart, liver, kidney and pancre-
as, where it begins its essential role in intracellular energy 
production. As all cellular activities depend on energy, 
CoQ
10
 is essential for the health of all organs and tissues 
(Ernster, Dallner, 1995). Several cofactors are involved 
in its synthesis, including vitamin B2, vitamin B6, folic 
acid, vitamin B12, niacin, panthotenic acid and vitamin C 
(Figure 2). The concentration of CoQ
10
 in human tissues 
reaches its peak at the age of twenty years, after which it 
progressively decreases.
CoQ
10
 can be found in most living organisms, and 
since its discovery in 1957 by Crane et al. and the iden-
tification of its chemical structure by Folkers et al. in 
1958, it has been extensively studied for its key role in 
cellular energy production – it is involved in the transport 
of electrons and protons and in the synthesis of ATP in the 
mitochondrial membrane - and acts as an antioxidant sca-
venger of free radicals (Kitano et al. , 2006; Shinde, Patil, 
Tendolkar, 2005, Hughes et al., 2002, Nohl et al., 2001).
Because CoQ
10
 is not classified as a vitamin or 
mineral, no dietary reference value or established daily 
recommended levels are available. However, some signs 
and symptoms are associated with a lack of CoQ
10
, such 
as congestive heart failure, ischemic heart disease, car-
diomyopathy, hypertension, hyperthyroidism and breast 
cancer (Quinzii, DiMauro, Hirano, 2007a). However, it 
is unclear whether the lack of CoQ
10
 contributes to the 
development of these diseases or is caused by the diseases.
The deficiency may occur as a result of low inges-
tion or inadequate production caused by aging or due to 
deficiency of the nutrients needed for its synthesis. Ge-
netic or acquired defects in its synthesis or metabolism, 
and interactions with medications such as beta-blockers, 
hydrochlorothiazide, methyldopa, statin and tricyclic an-
tidepressants may also reduce levels of CoQ
10
 (Quinzii, 
Hirano, DiMauro, 2007b).
FIGURE 1 - Structure of coenzyme Q
10
 (2,3-dimethoxy-5-
methyl-6-decaprenil-1,4-benzoquinone). Source: Shinde, Patil, 
Tendokar, 2005.
FIGURE 2 - Synthesis of coenzyme Q
10
. Human cells synthesize CoQ
10
 from the amino acid tyrosine, through eight steps which 
require adequate levels of vitamins such as folic acid, niacin, riboflavin and pyridoxine. A deficiency in any of these nutrients 
results in CoQ
10
 deficiency (adapted from Shinde, Patil, Tendokar, 2005).
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Coenzyme Q10 and aging
The property of CoQ
10
 to act both as a pro-oxidant 
and an antioxidant suggests that it may also be a modulator 
of cellular redox state under physiological or pathological 
conditions, and particularly, could play a role in the aging 
process (Sohal, Forster, 2007). During aging, pro-oxidant 
changes in cellular redox status take place, with a conse-
quent increase of oxidative damage in molecules (Sohal, 
Mockett, Orr, 2002). This hypothesis refers to the imbalan-
ce between the generation of pro-oxidant and antioxidant 
defense, and the level of oxidative stress that increases 
during aging; the mitochondria play a critical role in this 
homeostatic disturbance (Sohal, Dubey, 1994). The ele-
vation of the stress or oxidative damage due to increased 
production of O
2
·ˉ/H
2
O
2
, and the decline in mitochondrial 
ability to synthesize ATP, reduces the functional capacity 
of several physiological systems (Sohal, Forster, 2007).
There is a hypothesis that CoQ
10
 is involved in these 
age-related changes because it is a carrier of electrons and 
is, therefore, involved in the oxidative phosphorylation 
system as a generator and sequester of reactive oxygen 
species (ROS).
The results of several studies in the literature on 
age-related changes in levels of CoQ
10
 do not support 
the existence of a common trend. Kalen, Appelkvist and 
Dallner (1989) reported loss in CoQ
10
 content (related to 
age) in human tissue homogenates. Beyer et al. (1985) 
studied age-related changes in the levels of CoQ
10
 in 
several tissues and found no differences in homogenates 
of brain and lung of rats. However, there was an increase 
in the liver and a decrease in heart, kidney and skeletal 
muscles. The differences between the studies may be due 
to age of animals or the procedures used for extraction and 
quantification of CoQ
10
, or, differences between species, 
lines or diets.
Matthews et al. (1998a) showed that the intake 
of CoQ
10
 by rats with twelve or twenty-four months of 
age increased its content in brain mitochondria and had 
a neuroprotective effect against acid 3-nitropropionic 
(3-NPA). Several studies in young rats have shown that 
administration of CoQ
10
 by feeding caused an increase 
in the quantity of CoQ
10
 in plasma and homogenates and 
mitochondria of liver, heart and skeletal muscle (Kwong 
et al., 2002; Kamzalov et al., 2003; Rebrin, Sohal, 2004).
Antioxidant role of Coenzyme Q10
The mitochondrial inner membrane contains CoQ
10
 
and α-tocopherol, both possessing antioxidant properties. 
This raises questions on their respective roles in the seques-
tration of free radicals generated in the mitochondrial inner 
membrane. In solution, CoQ
10
 has been shown to inhibit 
lipid peroxidation in mitochondrial membrane depleted of 
α-tocopherol (Mellors, Tappell, 1966; Takayanagi et al., 
1980). Current evidence suggests that α-tocopherol and 
ubiquinol act in combination to scavenge free radicals 
during auto oxidation of mitochondrial membrane (Stoya-
novsky et al., 1995; Lass, Sohal, 1998; Sohal, 2004). The 
reduced form of CoQ
10
 is able to scavenge free radicals 
that can cause damage to DNA, proteins and lipids, as well 
as causing cardiovascular disease, and neurodegenerative 
diseases such as Alzheimer and Parkinson.
The intake of CoQ
10
 in the long term over a period 
spanning 3.5 to 25 months, had no effect on activities of 
main antioxidant enzymes such as catalase, glutathione 
peroxidase and superoxide dismutase in the liver, kidney, 
skeletal muscle or brain (Sohal, Forster, 2007).
The endogenous antioxidants are important to 
maintain the normal activities of cells and systems of the 
body. However, when exposed to alcohol, drugs, trauma, 
cold, infections, toxins, radiation, diet low in nutrients, 
or vigorous physical activity, the endogenous antioxidant 
defense cannot neutralize the oxidative stress, requiring 
supplementation of antioxidants from the diet (Kaliora, 
Dedoussis, Schmidt, 2006).
The mitochondrion is where most free radicals are 
produced in the cell. A small percentage of mitochondrial 
oxygen consumption results in the production of hydro-
gen peroxide (Somayajulu et al., 2005). Reactive oxygen 
species produced as subproducts of the mitochondrial 
electron transport chain are suppressed by antioxidants 
and converted into non-toxic compounds by enzyme 
scavengers of free radicals (Beal, 1999a; Sanders et al., 
1993). However, accumulation of free radicals in tissues 
can result in dysfunction and cell death. Excessive cell 
death is a feature of many neurological disorders in-
cluding stroke, ischemia, Parkinson’s and Alzheimer’s 
diseases.
Previous studies have indicated that neuronal cells 
are highly sensitive to reactive oxygen species such as free 
radicals (Kim, Won, Gwag, 2002). There is a hypothesis 
that mitochondrial dysfunction and the consequent produc-
tion of ROS can induce the neuronal cell death that occurs 
in neurodegenerative diseases (Somayajulu et al., 2005; 
Kitazawa, Ananth, Kanthasamy, 2003; Christen, 2000; 
Behl, 1999; Piantadosi, Zhang , 1996; Coyle, Puttafarcken, 
1993). Somayajulu et al. (2005) demonstrated that CoQ
10
 
protects the cells from apoptosis, both morphologically 
and biochemically. The first evidence that CoQ
10
 can exert 
neuroprotective effects in the central nervous system in 
vivo was reported in 1994 by Beal et al.
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Coenzyme Q10 and the Central Nervous System
The brain needs high energy and oxygen consump-
tion (Floyd, 1999). As a result, it is also replete with readily 
oxidized amino acids and unsaturated fatty acids, with the 
easy production of free radicals (Murata, Ohtsuki, Teraya-
ma, 2008). This makes the brain vulnerable to oxidative 
damage, and several recent articles suggest that oxidative 
stress plays a major role in the onset of neurodegenerative 
diseases related to aging.
The key role of CoQ
10
 in oxidative phosphorylation 
emphasizes its importance in the metabolism of neurons, 
given the constant and high energy demand of these cells. 
The nervous system is exposed to oxidative stress, and this 
may emphasize the role of CoQ
10
 in the central nervous 
system (Littarru, 2006). From clinical and pre-clinical stu-
dies, it is clear that oxidative stress and its consequences 
- oxidative damage in lipids, proteins, nucleic acids, - may 
be the cause, or at least a contributory factor, of a large 
number of neurodegenerative diseases (Coyle, Puttfarken, 
1993; Beal, 2005).
The neurodegenerative diseases include common 
and debilitating disorders, and are characterized by pro-
gressive and irreversible loss of neurons in specific regions 
of the brain. The most common neurodegenerative disor-
ders are Parkinson’s disease and Huntington´s disease, 
where the loss of neurons in the basal ganglia structures 
results in changes in the control of movement; Alzheimer’s 
disease, in which the loss of neurons in the hippocampus 
and the cortex leads to deficiency in memory and cogni-
tive capacity; and amyotrophic lateral sclerosis, in which 
muscle weakness results from the degeneration of motor, 
bulbar and cortical neurons (Littarru, 2006).
In several animal models of neurodegenerative dise-
ases including amyotrophic lateral sclerosis, Huntington’s 
disease and Parkinson’s disease, CoQ
10
 has a beneficial 
effect, reducing the progression of disease (Shults et al., 
2002; Kwong et al., 2002; Ferrante et al., 2002; Somaya-
julu et al., 2005).
Beal et al. (1994) injected malonic acid in striatum 
of laboratory animals, and found that this procedure in-
duced depletion of ATP and an increase in lactic acid. The 
administration of CoQ
10
 in animals was able to mitigate the 
depletion of ATP induced by malonate while minimizing 
the increase in concentrations of lactate.
Beal and Matthews (1997a) also examined whe-
ther CoQ
10
 can exert antioxidant effects in brain tissue. 
They demonstrated that oral supplementation with CoQ
10
 
(200 mg/kg/day) for one month significantly protected 
against the increase in the 2.5-dihydroxybenzoic acid 
(DHBA) induced by malonate. The DHBA is a biochemical 
marker for the generation of potent oxidative species such 
as hydroxyl radicals.
These data indicate that experimentally-induced le-
sion, as well as the changes caused by oxidative stress, can 
be neutralized by oral administration of CoQ
10
 in animals. 
It is well known that the administration of CoQ
10
 in young 
rats leads to a significant increase of CoQ
10
 in plasma and 
the liver (Beal, Matthews, 1997a, Zhang et al., 1995).
Beal et al. (1999a) found no increased concentra-
tions of CoQ
10
 in the brain of young animals supplemen-
ted with CoQ
10
 and this could be due to saturation of the 
membrane by CoQ
10
 in animals of this age. Furthermore, 
we know that aging in rats and humans leads to a decrease 
of CoQ
10
 in several tissues, including the brain (Kallen, 
Appelkvist, Dallner, 1989; Beyer et al., 1985). Indeed, 
Matthews et al. (1998a) conducted a study with supple-
mentation of CoQ
10
 in twelve-month-old rats and showed 
an increase in CoQ
9
 and CoQ
10
 in cerebral cortex. The 
extent of the increase (30-40%) almost restored the levels 
to those found in young animals.
Parkinson’s disease
First described by James Parkinson in 1817, 
Parkinson’s disease (PD) is a progressive neurological 
disorder characterized clinically by tremor, muscle rigi-
dity, slowness and lack of movement and a disability of 
postural balance that leads to changes in gait and fall. It 
is one of the most common neurological conditions the 
cause of which remains unknown. The prevalence of PD 
is approximately 0.3% of the population and of these, 1% 
is over 60 years of age. The incidence rate is 150-200 per 
100,000 persons per year, although this is increasing (de 
Lau, Breteler, 2006).
The main histopathological feature of PD is the 
selective loss of dopaminergic neurons of the substantia 
nigra in the central nervous system (Dawson, Dawson, 
2003; Cookson, 2005). The tyrosine hydroxylase, a key 
enzyme for the synthesis of dopamine, is also deficient. 
From a biochemical point of view it is known that the 
activity of mitochondrial complex I is selectively reduced 
in the substantia nigra of PD patients (Parker, Boyson, 
Parks, 1998; Schapira et al., 1990). This defect can cause 
a “leakage” of electrons from mitochondria, leading to an 
accumulation of ROS (Reactive Oxygen-Derived Species) 
that damages proteins, lipids and nucleic acids (Jenner, 
2003). Interestingly, this enzyme activity is reduced in 
platelets of patients with PD (Benecko, Strumper, Weiss, 
1993). The brain of PD patients also shows evidence 
of impaired proteasomal function, a defect that results 
in increased oxidative stress and decreased removal of 
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damaged polypeptides oxide (McNaught, Olanow, 2003; 
Halliwell, 2002; Farout, Friguet, 2006; Pope, Gomes, 
Rockwell, 2007).
Mitochondrial dysfunction and oxidative stress are 
considered important in the pathogenesis of PD. The initial 
hypothesis that the deficiency in mitochondrial complex I 
may be involved in the etiology of PD came from the dis-
covery that the complex I mitochondrial inhibitor MPTP 
(1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) causes a 
syndrome indistinguishable from PD and selective loss 
of dopaminergic cells in the substantia nigra (Langston 
et al., 1983).
The known position of CoQ
10
 in the respiratory 
chain, where it acts as electron acceptors for comple-
xes I and II / III, led the researchers at the University 
of California, San Diego, to check the level of CoQ
10
 in 
the mitochondria of platelets isolated from patients with 
PD. The level of CoQ
10
 mitochondrial in these patients 
(141.8 ng/mg protein ± 11.3) was lower than in controls 
(216.3 ± 12.7). This difference was highly significant, and 
in addition, there was a significant correlation between 
concentrations of CoQ
10
 and the activities of complex I 
and complex II / III. It is important to emphasize that the 
platelets reflect certain biochemical processes that occur in 
the brain (Shults, Haas, Beal, 1999). Sohmiya et al. (2004) 
had observed some years before, a deficiency of CoQ
10
 in 
the plasma of PD patients.
In order to ascertain whether the treatment with 
CoQ
10
 could benefit patients with PD, Shults et al. (1999) 
first investigated whether oral administration of CoQ
10
 
might be beneficial in a laboratory model of PD. MPTP is 
a chemical agent selectively toxic to dopaminergic neurons 
and the first to be impaired in PD. A group of one-year-old 
rats were treated with CoQ
10
 (200 mg/kg per day) and also 
received MPTP. The levels of dopamine in the striatum 
were significantly higher (37%) in the group of rats treated 
with CoQ
10
 and MPTP, compared to the group treated only 
with MPTP. Based on these observations, a preliminary 
study was conducted in fifteen PD patients supplemented 
with CoQ
10
 for a month. The complex I / citrate synthase 
in mitochondria isolated from platelets of patients after 
treatment with CoQ
10
 was higher than the corresponding 
activity before treatment, and similar to the activity found 
in the control group.
All these observations in laboratory animals and 
patients led to a study with a larger number of patients 
(80) to verify if CoQ
10
 could slow the progression of PD. 
This study reported that the intake of 1200 mg per day of 
CoQ
10
 for sixteen months was associated with 44% less 
functional decline in PD patients, including in daily activi-
ties (Shults, 2002). Another study in twenty-eight patients 
with PD also showed moderate improvement in symptoms 
with daily oral administration of 360 mg of CoQ
10
 (Muller 
et al., 2003). While these data are promising, they need 
to be confirmed in larger clinical trials before the use of 
CoQ
10
 can be recommended for PD, but support the idea 
that high levels of CoQ
10
 could yield therapeutic benefits.
Alzheimer’s disease
Alzheimer’s disease (AD) is a degenerative disease 
of the brain and the most common cause of dementia in 
the elderly, affecting approximately 200 million people 
worldwide and causing cognitive disabilities with gradual 
onset (Evans et al., 1989; Hebert et al., 2001). In general, 
the first clinical aspect is memory deficiency, where remote 
memories are preserved relatively well in the course of 
the disease. The patient’s degree of alertness or lucidity 
is not affected until the disease is very advanced (Francis 
et al., 1999).
The pathophysiology of AD is complex and inclu-
des a defect in b-amyloid protein metabolism (Ab), irre-
gularities in neurotransmission, and the involvement of 
inflammatory, oxidative and hormonal pathways (Cutler, 
Sramek, 2001).
Oxidative stress, an imbalance between the forma-
tion of free radicals and the antioxidant system, plays a 
critical role in the pathogenesis of AD (Gary, Hsueh-Meei, 
2005; Butterfield, 2004). Kawamoto et al. (2005) conduc-
ted a study involving oxidative stress and AD, and found 
that patients with AD compared with elderly controls, sho-
wed an increase in the production of TBARS (thiobarbitu-
ric acid reactive substances), as well as in the activities of 
NOS (nitric oxide synthase), SOD (superoxide dismutase) 
and Na / K-ATPase. However, no change was found in the 
basal content of cGMP (cyclic guanosine monophosphate). 
Thus, they concluded that there is a break in the modu-
lation of systemic oxidative stress during aging, and that 
this disruption is more pronounced. As oxidative damage 
is involved in the etiology of neurologic complications, 
treatment with antioxidants has been used as a therapeutic 
approach in several types of neurodegenerative diseases, 
including AD (Ahmad et al., 2005; Ansari et al., 2004).
It has been shown that CoQ
10
 improves cognitive 
functions, regulates mitochondrial functions and faci-
litates the synthesis of ATP (McDonald, Sohal, Forster, 
2005). CoQ
10
 significantly attenuates the depletion of ATP 
and malonate-induced increases of lactate in brain mito-
chondria of rats (Beal et al., 1994). Supplementation of 
CoQ
10
 in rats increased the endogenous content of CoQ
10
 
in the brain and provided antioxidant protection against 
free radical generation (Kwong et al., 2002; Lenaz et al., 
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1999; Rauscher, Sanders, Watkins, 2001; Somayajulu et 
al., 2005).
Söderberg et al. (1992) found increased levels of 
CoQ
10
 in most brain regions of patients with Alzheimer’s 
disease. A recent study by Bustus et al. (2000) found no 
significant difference in plasma levels of CoQ
10
 in pa-
tients with Alzheimer’s disease and controls. According 
to Isharat et al. (2006), CoQ
10
 supplementation improves 
learning and memory deficits by possibly inhibiting oxi-
dative stress, and also improves levels of ATP, being an 
important therapy in the treatment of AD.
Promising preliminary evidence from studies in 
humans suggests that supplementation with CoQ
10
 may 
reduce, but not cure, dementia in individuals with AD. 
Additional well-designed studies are needed to confirm 
these results before a recommendation can be made.
Huntington’s disease
Huntington’s disease (HD) is an inherited neurode-
generative disorder. It was given the name of the physician 
George Huntington, who described it in 1872. In 1993 the 
gene causing the disease was identified (Browne, Ferranti, 
Beal, 1999).
Huntington’s disease is an autosomal dominant 
phenotype, with the gene called IT15 responsible for the 
disease, located at the short arm of chromosome 4. The 
mutant gene is constituted by abnormal repetitions of the 
sequence of nucleotides cytosine, adenosine and guanine 
(CAG), responsible for encoding glutamine (Beal, 1995). 
The number of CAG repetitions is considered normal up 
to thirty, while in HD the number of repetitions is usually 
greater than thirty-six. It has been observed that the larger 
number of repetitions of the trinucleotide CAG, the ear-
lier the manifestation of the disease (Goldberg, Telenius, 
Hayden, 1994).
The mechanism by which mutations of this gene 
causes HD remains undefined, although evidence of ani-
mal models and clinical trials indicate a role of oxidative 
stress and impaired mitochondrial function (Kasparov et 
al., 2006). The gene defect may cause a slight reduction 
in the capacity of energy metabolism, leading to neuronal 
degeneration, primarily in the striatum and then in other 
regions of the brain (Jenkins et al., 1998). The impaired 
energy production leads to increased intracellular calcium 
and generation of free radicals, however the exact mecha-
nism for the decreased capacity of energy in HD is unclear.
Clinically, this disease is characterized by psychia-
tric and behavioral disorders, cognitive dysfunction 
(thinking, hearing, memory) and progressive dementia. 
The prevalence of HD is of 3-7 per 100,000, and the annual 
incidence is 0.2-0.7 per 100,000 (Cardoso et al., 2006). 
The symptoms of the disease may appear at any stage 
of life, but in most cases, disease onset typically occurs 
between forty and fifty years of age with average survival 
of fifteen to twenty years (Duyao et al., 1993).
Patients with HD have elevated levels of lactate in 
the brain. The measurement of lactate production in the 
brains of HD patients done by H-MRS (Proton (H+) Mag-
netic Resonance Spectroscopy) has revealed that creatine, 
cyclocreatine, CoQ
10
 and nicotinamide - compounds that 
increase energy metabolism - could exert neuroprotective 
effects in this disease (Koroshetz et al., 1997; Matthews 
et al., 1998b; Beal, 1999b).
CoQ
10
 has been shown effective in reducing the 
damage produced by toxins that inhibit complex II, pre-
venting the depletion of ATP and increases in lactate (Beal 
et al., 1994; Matthews et al., 1998a). CoQ
10
 also prolonged 
survival while delaying the onset of motor impairment in 
a HD model in transgenic mice (Ferrante et al., 2002).
The neuropathological and clinical symptoms of 
HD can be simulated in animal models, with the systemic 
administration of 3-nitropropionic acid (3-NP). Kasparov 
et al. (2006) studied the activity of creatine kinase (CK) 
and mitochondrial respiratory chain function in the brain 
of aged rats administered with 3-NP, with and without 
prior application of antioxidants CoQ
10
 + Vitamin E. They 
found that the content of CoQ
10
 in tissues decreased in rats 
that received 3-NP. Antioxidants CoQ
10
 + Vitamin E were 
effective in preventing the decrease of CoQ
10
 content in 
brain tissue, but failed to prevent the decline in function 
of the respiratory chain.
Pre-treatment with a-tocopherol caused no neuro-
protective effect in an animal model of HD (Beal et al., 
1988), and treatment with high doses of a-tocopherol was 
effective only in patients in early stages of the disease 
(Peyser et al., 1995). Moreover, pre-treatment with CoQ
10
 
exerted neuroprotective effects in a variety of animal 
models of HD and the oral administration of CoQ
10
 signi-
ficantly reduced the elevated levels of lactate in patients 
with HD (Beal, 1999b). Levels of CoQ
10
 in the serum of 
HD patients were significantly lower than in both healthy 
controls and patients with HD treated with CoQ
10
 (Andrich 
et al., 2004).
A six-month pilot test assessed the tolerability of 
CoQ
10
 (Feigin et al., 1996). Ten subjects with sympto-
matic HD received 600 mg of CoQ
10
 per day, in three 
doses. The individuals were assessed three times: before 
the administration of CoQ
10
; and after three and six mon-
ths of treatment, using the Scale for the Assessment of 
Huntington’s disease, the HD Functional Capacity Scale, 
and neuropsychological tests. All subjects completed the 
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study, with some mild adverse effects including heartburn, 
fatigue, headache, and increased involuntary movements. 
When the results of motor and functional scales obtained 
before the administration of CoQ
10
 and after six months 
were compared, no significant effect was observed. Howe-
ver, this study was small and unable to detect such effects.
As mentioned previously, HD patients have high 
levels of lactate in the brain. The administration of 
360 mg/d of CoQ
10
 for two to eight weeks was associated 
with decreased levels of lactate in the occipital cortex in 
fifteen out of eighteen subjects (Koroshetz et al., 1997). 
Following interruption of administration of CoQ
10
, levels 
returned to baseline values, indicating that these effects 
were due to CoQ
10
. These results regarding the ability of 
CoQ
10
 to change the levels of cortical lactate support the 
therapeutic potential of CoQ
10
 for HD treatment.
Amyotrophic lateral sclerosis
Amyotrophic lateral sclerosis (ALS) is a progressive 
neurodegenerative disease characterized by degeneration 
of motor neurons in the spinal cord, brainstem and motor 
cortex, resulting in progressive muscle weakness and 
atrophy, observed as loss of muscle mass with progressive 
difficulty in performing movements, and loss of muscle 
strength. The incidence of ALS is approximately one to 
two cases per 100,000 per year, with onset typically at 
around the age of sixty years, with survival of three to five 
years (Rowland, Shneider, 2001; Sorenson et al., 2002)
ALS can occur in sporadic or familial form, which 
corresponds to only ten percent of cases. The possible 
involvement of free radicals in the etiology of ALS is 
suggested by the discovery that mutations in the gene en-
coding the antioxidant enzyme superoxide dismutase Cu / 
Zn (SOD1) are associated with familial ALS (Rosen et al., 
1993). In both cases (sporadic or familial), although the 
etiology of ALS is not well known, several recent studies 
suggest an increase in oxidative damage (Bogdanov et al., 
2000; Beal et al., 1997b; Ferrante et al., 1997).
According to Murata, Ohtsuki and Terayama (2008), 
mitochondrial oxidative damage contributes to the patho-
genesis of sporadic ALS. The concentrations of oxidized 
and reduced CoQ
10
 in the cerebrospinal fluid were measu-
red by high performance liquid chromatography in thirty 
patients with ALS and seventeen controls without neuro-
logical diseases. The percentage of oxidized CoQ
10
 in the 
cerebrospinal fluid of patients with ALS was significantly 
higher than in controls.
High levels of oxidized CoQ
10
 in plasma were found 
in patients with sporadic ALS, consistent with oxidative 
stress (Sohmiya et al., 2005). Given the evidence of 
mitochondrial dysfunction and oxidative stress in the pa-
thogenesis of ALS, CoQ
10
 has been studied as a possible 
therapeutic approach (Galpern, Cudkowicz, 2007). The 
development of non-toxic drugs to block the oxidative in-
jury may interrupt the process of disease at an early stage.
Studies using animal models of ALS have suggested 
that CoQ
10
 may be effective in dealing with this problem. 
In a transgenic mice model with a SOD1 mutation, sup-
plementation with 200 mg/kg of CoQ
10
 increased survival, 
suggesting a potential therapeutic role of CoQ
10
 in patients 
(Matthews et al., 1998a). Recently, a systematic review of 
candidate therapeutic agents for ALS was conducted, and 
CoQ
10
 has been identified as one of twenty agents priori-
tized for research in clinical trials (Traynor et al., 2006).
CONCLUSION
While data from pilot studies are encouraging, it is 
important to note that the results of these studies are not 
conclusive and more studies are needed before CoQ
10
 can 
be recommended as effective to patients, without exposing 
them to unnecessary risks and significant costs.
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